Skip to main content
Premium Trial:

Request an Annual Quote

Waters Enters into Agreement Increasing Revolving Facility by $200M

NEW YORK (GenomeWeb News) – Waters said today in a document filed with the US Securities and Exchange Commission that it entered into an Incremental Commitment Agreement to increase its revolving facility to $900 million from $700 million.

The Incremental Commitment Agreement is associated with a $1 billion credit agreement that Waters entered into with various lenders last year. The original agreement provided the company with a five-year, unsecured $300 million term loan facility and a $700 million revolving facility. The agreement allows Waters to request increases in commitments from lenders of no less than $25 million up to an aggregate additional amount of $250 million.

The term loan facility and the revolving facilities mature on July 28, 2016. JP Morgan Chase Bank was the administrative agent on the credit agreement, and JP Morgan Europe was the London agent.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.